Page 221 - Read Online

Leon et al. Neuroimmunol Neuroinflammation 2018;5:30 I http://dx.doi.org/10.20517/2347-8659.2018.26 Page 5 of 7

age, superior verbal learning abilities, improved recall memory, faster processing of information, better test
performance, and reduced accumulation of amyloid pathology in the aged brain. Furthermore, a second in-
novative approach would be to create a more advanced antibody targeting specifically the 133-152 N-terminal
binding region of ApoE to prevent interaction between LDLR and ApoE. In sum, modulation of ApoE struc-
ture to create and/or enhance ApoE2-like activity may shed light on a novel approach for AD treatment and
prevention.

DECLARATIONS
Authors’ contributions
Reviewed the literature and wrote this article: Leon M
Edited and added further information to this article: Sawmiller D, Giunta B
Contributed to the initial idea of the review: Tan J
Read and approved this article: all authors

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by the NIH/NIA (R21AG049477, JT) and Silver Endowment (JT). JT holds the Sil-
ver Chair in Developmental Neurobiology.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Sato N, Morishita R. The roles of lipid and glucose metabolism in modulation of B-Amyloid, tau, and neurodegeneration in the patho-
genesis of Alzheimer disease. Front Aging Neurosci 2015;7:199.
2. Shafiei SS, Guerrero-Munoz MJ, CastilloCarranza DL. Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Front Ag-
ing Neurosci 2017;9:83.
3. Hoglund K, Kern S, Zettergren A, BorjessonHansson A, Zetterberg H, Skoog I, Blennow K. Preclinical amyloid pathology biomarker
positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry 2017;7:e995.
4. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinistö L, Halonen P, Kontula K. Apolipoprotein E, de-
mentia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-7.
5. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ. Apolipoprotein E-dependent accumulation of Al-
zheimer disease-related lesions begins in middle age. Ann Neurol 2009;65:650-7.
6. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9:106-
18.
7. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the
liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A 1985;82:203-7.
8. Zhao N, Liu C, Qiao W, Bu G. Apolipoprotein E, receptors and modulation of Alzheimer’s disease. Biol Psychiatry 2018;83:347-57.
9. Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation
and posttranslational modification. Biochemistry 1981;20:1033-41.
10. Khan W, Giampietro V, Banaschewski T, Barker GJ, Bokde AL, Büchel C, Conrod P, Flor H, Frouin V, Garavan H, Gowland P, Heinz A,
Ittermann B, Lemaître H, Nees F, Paus T, Pausova Z, Rietschel M, Smolka MN, Ströhle A, Gallinat J, Vellas B, Soininen H, Kloszewska